Myelofibrosis

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

Featured

Sponsored
Fadi Haddad, MD
Sponsored
Myelofibrosis Caregiver Interview Series: Involving Patients and Caregivers in Myelofibrosis Treatment Plans
04/24/2026
In the next installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD, emphasizes a patient- and caregiver-centered approach to treatment planning—highlighting how clinical decisions...
04/24/2026
Sponsored
Tim F. and Fadi Haddad, MD
Sponsored
Myelofibrosis Caregiver Interview Series: Monitoring Myelofibrosis Treatment Effectiveness
04/21/2026
Fadi G. Haddad, MD
Monitoring treatment response in myelofibrosis requires a balanced assessment of patient-reported symptoms, objective scoring tools, hematologic parameters, and spleen size. In part 1 of this Myelofibrosis...
04/21/2026
Sponsored
Tim F and Dr Haddad
Sponsored
Myelofibrosis Caregiver Interview Series: Caregiver Input for Myelofibrosis Treatment Plans
03/31/2026
In the final installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD interviews Tim F., a caregiver from Pittsburgh, PA, about the critical role caregivers play in shared...
03/31/2026

Interactive Features

Pop Quiz
Myelofibrosis
Pop Quiz
Which JAK Inhibitor Remains the Standard of Care in Myelofibrosis?
09/25/2025
Miranda Manier, BA
In an interview with Consultant360, Junaid Anwar, MD, a hematology-oncology fellow at UT Health Houston, reviewed the current evidence base for JAK inhibitors in myelofibrosis from a pooled analysis of five...
09/25/2025

Clinical Insights

Sponsored
Fadi Haddad, MD
Sponsored
Myelofibrosis Caregiver Interview Series: Involving Patients and Caregivers in Myelofibrosis Treatment Plans
04/24/2026
In the next installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD, emphasizes a patient- and caregiver-centered approach to treatment planning—highlighting how clinical decisions...
04/24/2026
Sponsored
Tim F. and Fadi Haddad, MD
Sponsored
Myelofibrosis Caregiver Interview Series: Monitoring Myelofibrosis Treatment Effectiveness
04/21/2026
Fadi G. Haddad, MD
Monitoring treatment response in myelofibrosis requires a balanced assessment of patient-reported symptoms, objective scoring tools, hematologic parameters, and spleen size. In part 1 of this Myelofibrosis...
04/21/2026
Sponsored
Tim F and Dr Haddad
Sponsored
Myelofibrosis Caregiver Interview Series: Caregiver Input for Myelofibrosis Treatment Plans
03/31/2026
In the final installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD interviews Tim F., a caregiver from Pittsburgh, PA, about the critical role caregivers play in shared...
03/31/2026
Sponsored
Tim F.
Sponsored
Myelofibrosis Caregiver Interview Series: The Impact of Myelofibrosis on Caregivers
03/31/2026
In the latest installment of the Myelofibrosis Caregiver Interview Series, Tim F. from Pittsburgh, PA, talks with Fadi Haddad, MD about the caregiver perspective, highlighting the substantial day-to-day...
03/31/2026
Expert Q&A
Brady L Stein, MD
Expert Q&A
How the ASH Clinical Practice Guidelines Aim to Improve Myelofibrosis Management
12/22/2025
Brady L. Stein, MD
At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
12/22/2025